Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Revenue comes from direct sales of its approved drugs through outside distributors, concentrated in its home market and among a small number of distribution customers who account for most of that revenue. By its own reporting, its research spending still exceeds the revenue those sales generate.

CompanyGraph reads scale here as something that does not grow continuously with sales volume, but moves in steps: years of research produce nothing sellable until a drug clears regulatory approval, after which it can be sold broadly without a matching new round of research spending. Clearing approval for a drug in an additional geography or patient group works the same way, as a discrete unlock rather than gradual growth.

The company depends on outside suppliers for research materials and drug ingredients, on outside contract manufacturers to produce its drugs while it builds its own factory, on outside clinical-trial sites and patient recruitment, on keeping a small base of specialized technical staff, and on continued regulatory approval and financing. It does not name these suppliers or manufacturers itself.

A small number of unnamed distribution customers account for most of its sales, concentrating its revenue on very few counterparties. By its own description, its approved drugs are the only authorized option for certain patient groups in their specific indications, making those patients dependent on this company for that particular treatment.

CompanyGraph cannot verify what a competitor could or could not replicate; what is visible is position, this company sits among a large group of similarly structured drug developers that all work under the same research-to-approval model, making the broad shape of its business common rather than rare. Its own claim of being the sole approved option in specific narrow indications describes its market position, not something CompanyGraph can independently confirm about the underlying business itself.

By its own description, one of its approved drugs is the only approved oral targeted option for a specific genetic subtype of lung cancer in both its home market and the market where it later gained approval, while another is described as the only highly selective drug of its kind approved for a specific blood cancer that has already been treated once and returned. Where that description holds, prescribers and patients have no alternative approved drug of the same kind to switch to, though this is the company's own characterization rather than something confirmed independently.

By its own account, what limits this company's growth is not a single physical bottleneck but a chain of gates: enrolling and running clinical trials, clearing regulatory approval, then achieving market acceptance and sales execution, while also needing to retain specialized technical staff, secure research materials from outside suppliers, and maintain enough working capital to fund all of this before its drugs earn enough to cover it. This matches the broader pattern for companies whose revenue depends on clearing a regulatory approval gate before a product can be sold at all.

By its own account, the risks it lists first are continuing to operate at a loss or seeing that loss deepen, and losing the specific technical edge or key people behind its current drugs. Separately, it discloses that a very small number of unnamed customers account for most of its sales, so losing any one of them would concentrate the damage rather than spread it thinly across many buyers.

By its own account, regulators that approve its drugs for sale, set the price and insurance terms they can be sold under, and license its manufacturing site act on this company directly, in both its home market and the market where its lead drug also gained approval, and it separately names movement in the exchange rate against the US dollar and a few smaller currencies as a pressure it tracks. More broadly, this sits within a wider pattern of needing to clear a regulatory approval before any drug can be sold at all.